BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
May 02, 2011
 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

BTG plc (LSE:BGC) gained 4.90p to 248.4p last week after FDA approved an NDA from Centocor Ortho Biotech Inc. for Zytiga abiraterone acetate in combination with prednisone to treat metastatic, castration-resistant prostate cancer (CRPC) in patients who have been treated with docetaxel. Centocor is a subsidiary of Johnson & Johnson (NYSE:JNJ), which gained the program through its 2009 acquisition of Cougar Biotechnology Inc. Cougar received rights to abiraterone from BTG, which is eligible for milestones and royalties.

CRPC play Medivation Inc. (NASDAQ:MDVN) was up $1.69 to $24.70 last week. The company's MDV3100, which is partnered with Astellas Pharma Inc. (Tokyo:4503), is in Phase III testing.

Columbia Laboratories Inc. (NASDAQ:CBRX) was up $0.05 to $3.49 last week after submitting an NDA to FDA for Prochieve vaginal progesterone gel to prevent preterm birth in women with short uterine cervical length in the mid-trimester of pregnancy. Columbia requested Priority Review.

Endocyte Inc. (NASDAQ:ECYT) gained $2.39 (25%) to $11.88 on Tuesday after announcing plans to submit applications in the EU for its lead cancer candidate and companion diagnostic based on data from the Phase II PRECEDENT trial. The study showed EC145 plus chemotherapy met the primary endpoint of improving progression-free survival (PFS).

After consulting with EMA,...

Read the full 1050 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >